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Increased gastrin-releasing peptide (GRP) receptor expression
in tumour cells confers sensitivity to [Arg6,D-Trp7,9,NmePhe8]-
substance P (6 –11)-induced growth inhibition
CM Waters1, AC MacKinnon1, J Cummings2, U Tufail-Hanif1, D Jodrell2, C Haslett1 and T Sethi*,1
1Lung Inflammatory Group, Centre for Inflammation Research, University of Edinburgh Medical School, Hugh Robson Building, George Square, Edinburgh
EH8 9XD, UK; 2Cancer Research UK, Medical Oncology Unit, Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, UK
[Arg6,D-Trp7,9,NmePhe8]-substance P (6–11) (SP-G) is a novel anticancer agent that has recently completed phase I clinical trials.
SP-G inhibits mitogenic neuropeptide signal transduction and small cell lung cancer (SCLC) cell growth in vitro and in vivo. Using the
SCLC cell line series GLC14, 16 and 19, derived from a single patient during the clinical course of their disease and the development
of chemoresistance, it is shown that there was an increase in responsiveness to neuropeptides. This was paralleled by an increased
sensitivity to SP-G. In a selected panel of tumour cell lines (SCLC, non-SCLC, ovarian, colorectal and pancreatic), the expression of
the mitogenic neuropeptide receptors for vasopressin, gastrin-releasing peptide (GRP), bradykinin and gastrin was examined, and
their sensitivity to SP-G tested in vitro and in vivo. The tumour cell lines displayed a range of sensitivity to SP-G (IC50 values from 10.5
to 119 mM). The expression of the GRP receptor measured by reverse transcriptase–polymerase chain reaction, correlated
significantly with growth inhibition by SP-G. Moreover, introduction of the GRP receptor into rat-1A fibroblasts markedly increased
their sensitivity to SP-G. The measurement of receptor expression from biopsy samples by polymerase chain reaction could provide a
suitable diagnostic test to predict efficacy to SP-G clinically. This strategy would be of potential benefit in neuropeptide receptor-
expressing tumours in addition to SCLC, and in tumours that are relatively resistant to conventional chemotherapy.
British Journal of Cancer (2003) 88, 1808 – 1816. doi:10.1038/sj.bjc.6600957 www.bjcancer.com
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Despite recent advances in cytotoxic drug development, it is a
universal goal to develop novel cancer therapies that are more
specific to cancer cells and produce minimal damage to
nonmalignant cells. One approach to realising this goal is the
development of drugs that are able to block the growth-promoting
effects of cancer cell mitogens.
Neuropeptides are important growth factors in a number of
cancers including breast, colon, pancreatic, prostate, renal, gastric
carcinoma and small-cell lung cancer (SCLC). SCLC cells
proliferate in response to a range of neuropeptide growth factors,
and in many cases these neuropeptides are involved in autocrine
and paracrine growth loops that fuel unrestrained proliferation
(Moody et al, 1985; Sethi and Rozengurt, 1991; Sethi et al, 1992,
1993; North et al, 1997). Drugs that target specific mitogenic
neuropeptides have shown little promise. Monoclonal antibodies
have been developed against circulating bombesin and one such
antibody, 2A11, has been shown to inhibit the growth of SCLC in
vitro and also as xenografts in nude mice (Chaudry et al, 1999);
however, it has limited efficacy in human trials. Thus, ‘broad-
spectrum’ neuropeptide receptor antagonists have been the main
focus of research in this drug development strategy. Synthetic
analogues of substance P, for example, [Arg6,D-Trp7,9,NmePhe8]-
substance P (6–11) (SP-G), were initially identified as antagonists
of substance P-mediated cellular effects and were subsequently
found to also antagonise the cellular effects of bombesin (Jensen
et al, 1984). When tested in SCLC cell lines, it was found that
several substance P analogues inhibited calcium mobilisation
stimulated by the neuropeptides: bombesin, bradykinin, gastrin,
galanin, vasopressin, cholecystokinin and neurotensin (Woll and
Rozengurt, 1988; Langdon et al, 1992; Sethi et al, 1992). They were
also found to inhibit mitogenesis by the same range of
neuropeptides in both Swiss 3T3 cells and SCLC cells (Woll and
Rozengurt, 1988; Bepler et al, 1989; Sethi et al, 1992).
In addition to the in vitro growth-inhibitory effects of substance
P analogues, these compounds inhibit the growth of tumours in
xenograft models in nude mice (Langdon et al, 1992; Jones et al,
1997). SP-G has recently completed a phase I clinical trial and will
be entering a phase II clinical trial in SCLC in the near future (Clive
et al, 2001). The exact mechanism by which these compounds exert
their antitumour effects are unknown, but we have previously
shown that they act as ‘biased’ agonists inhibiting neuropeptide-
stimulated growth while directly stimulating apoptosis (Tallett
et al, 1996; MacKinnon et al, 1999, 2001). Understanding the exact
manner in which substance P analogues modulate neuropeptide
receptor signalling will allow for the rational design of more potent
analogues. Identification of biological features in tumours that
confer sensitivity to SP-G will elucidate the most effective use of
this group of compounds in clinical practice.
In this study, we measured the expression of the mitogenic
neuropeptide receptors for vasopressin (V1A), gastrin-releasing
peptide (GRP), bradykinin (BK2) and gastrin by reverse
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transcriptase –polymerase chain reaction (RT–PCR), and show
that GRP-receptor expression predicts sensitivity to SP-G in a
variety of tumours (SCLC, non-small-cell lung cancer (NSCLC),
colorectal, ovarian and pancreatic) in vitro and in vivo. Our results
suggest that an antineuropeptide growth factor strategy may be
effective in a wider range of tumours and may also be of benefit in
these neuropeptide-expressing tumours, which have acquired
relative resistance to conventional chemotherapeutic agents.
MATERIALS AND METHODS
Materials
Rat-1a cells and rat-1a cells stably expressing the mouse bombesin/
GRP receptor (GRPR) (BOR-15) were established by the Imperial
Cancer Research Fund (ICRF, London, UK). RPMI-1640,
Dulbecco’s essential Eagle’s medium (DMEM), bombesin and
vasopressin were from Sigma (Poole, UK). SP-G was a kind gift
from Peptec (Copenhagen, Denmark). All other reagents were of
the purest grade available.
Cell culture
Stocks were maintained in RPMI-1640 (tumour cell lines) or
DMEM (nontumour cell lines) supplemented with 10% (v v1) fetal
bovine serum (heat-inactivated at 571C for 1 h) 50 U ml1
penicillin, 50 mg ml1 streptomycin and 5 mg ml1 L-glutamine in
a humidified atmosphere of 5% CO2 : 95% air at 371C. For
experimental purposes, cells were either grown in SITA medium
(RPMI-1640 medium supplemented with 30 nM selenium, 5 mg ml1
insulin, 10 mg ml1 transferrin media supplement and 0.25%
bovine serum albumin (tumour cell lines)) or with 0.1% (v v1)
fetal bovine serum in DMEM (nontumour cell lines). Rat-1A
fibroblasts stably transfected with the mammalian bombesin
receptor (BOR-15 cells) were cultured in the presence of
400mg ml1 G418-sulphate.
Growth assays
Liquid growth was determined in SITA medium in the presence or
absence of mediators. Cell number was determined using a Coulter
Counter (model Z1, Beckman Coulter, Bucks, UK). Colony growth
was determined in 0.3% agarose in SITA medium for 21 days as
described by Sethi and Rozengurt (1991).
Determination of intracellular Ca2þ concentration
Intracellular Ca2þconcentration was determined using the fluor-
escent indicator Fura-2-tetraacetoxymethylester AME (FURA-2-
AM 1 mM) as described (Sethi et al, 1993) Ratiometric fluorescence
was monitored in a Perkin-Elmer Fluorometric Spectrophotometer
with dual excitation wavelengths of 340 and 380 nm and emission
wavelength of 510 nm.
Xenograft activity
Female nu/nu mice (6 weeks old) (ICRF, London, UK) were
maintained in negative pressure isolators (Moredun Animal
Research Unit, Edinburgh, UK). All xenografts used throughout
were initially established by subcutaneous injection of 107 cells
from their respective cell lines and then maintained by serial
passage of fragments of viable tumour as described previously
(Langdon et al, 1992).
Mice were allocated into control and treatment groups contain-
ing six to eight mice. Treatment started when the xenografts
reached a diameter of 3– 10 mm with the first day of peptide
administration designated as day 0. SP-G was dissolved in sterile
distilled water at a concentration of 10 mg ml1 and administered
by i.p. injection in a volume of 0.1 ml per 20 g of body weight to
yield a dose of 50 mg kg1. The dose schedule employed was twice
daily injections with an 8 h gap for a total of five injections. This
schedule was chosen based largely on the pharmacokinetics of
SP-G in nu/nu mice (Cummings et al, 1995). Controls received the
same dose schedule of vehicle. Xenografts were measured either
two or three times a week by means of calipers and tumour volume
(V) was then calculated by the formula V¼ p/6LW2, where L is the
longest diameter and W the diameter perpendicular to L. Results
were expressed as a relative tumour volume (RTV) which is defi-
ned simply as: V on day x/V on day 0, with RTV¼ 1 on day 0. Xeno-
graft experiments were repeated on two or three separate occasions.
Semiquantitative RT–PCR
RNA was extracted using Tri-Reagent (Sigma, Poole, UK) from
exponentially growing cells, which had been in SITA medium for
3–5 days and was subsequently treated with DNase1 to remove
any DNA contamination. cDNA was produced from this RNA
using a first-strand synthesis kit (Boehringer Mannheim, Roche,
UK). PCR primers used were: GRPR sense 50-ATCTTCTGTA-
CAGTCAAGTCC-30, antisense 50-GCTTTCCTCATGGAAGGGATA-
30; V1AR sense 50-TACCTGCTACGGCTTCATCTGC-30, antisense
50-ACACAGTCTTGAAGGAGATGGC-30; BK2R sense 50-
CCTGAGTGTCATCACCTTCTGC-30, antisense 50-TTGATGA-
CACGGCAGAGG-30; receptor for gastrin (gastrinR) sense 50-
CCTATCTCCTTCATTCACTTGC-30, antisense 50-AGTGTGCT-
GATGGTGGTGTAGC-30; g-actin sense 50-ATGGCATCGTCAC-
CAACTGG-30, antisense 50-ATGACAATGCCAGTG-GTGGC-30.
Polymerase chain reaction products were run on a 1.5% agarose
gel containing 1 mg ml1 ethidium bromide. Stored images of the
gels were analysed by densitometry using Gel Base/Gel Blot
software. g-Actin levels were measured as an internal control. Each
product was expressed relative to the levels of g-actin for the same
cDNA batch and for each PCR reaction.
RESULTS
Neuropeptide sensitivity in the longitudinal cell lines
GLC14, 16 and 19
The GLC14, 16 and 19 cell lines are SCLC cell lines established
from one patient during longitudinal follow-up (Berendsen et al,
1988). During this period, the tumour changed from sensitive
to resistant to chemotherapy, and the in vitro sensitivity to
chemotherapeutic agents reflected the clinical resistance to
treatment (de Vries et al, 1989 and T.S. observations (results not
shown)). Initially, neuropeptides (at a concentration of 100 nM) in
each of the three cell lines were screened for their ability to
increase [Ca2þ ]i. Table 1 and Figure 1A show that the GLC14 cell
line responded to bradykinin and serum resulting in a large
increase in [Ca2þ ]i and smaller responses were seen in case of
neuropeptides CCK, GRP and neuromedin B. No Ca2þ mobilisa-
tion was observed in response to neurotensin, substance P or
vasopressin. However, in the GLC19 line, addition of neuropep-
tides bradykinin, CCK, GRP, neuromedin B and substance P
caused large increases in [Ca2þ ]i. Vasopressin and neurotensin
caused smaller but consistent increases in [Ca2þ ]. The GLC19 was
the only cell line in which neurotensin caused a measurable
increase in [Ca2þ ]i.
One percent serum caused a rapid increase in [Ca2þ ]i in all
three cell lines of 100–150 nM, suggesting that the mobilisable
Ca2þ pools were equivalent in each line; however bombesin,
neuromedin B and CCK showed an increased responsiveness in the
GLC19 cells. Typical concentration response curves in GLC16 and
19 cells are shown in Figure 1B. Thus, during the tumour
progression from GLC14, 16 to 19 cell lines, there is an increase in
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Table 1 Neuropeptide Ca2+ mobilisation in the SCLC GLC longitudinal cell line series
Ca2+ mobilising
neuropeptides GLC14 GLC16 GLC19
Bombesin 673 (n¼ 7) 25759 (n¼ 7) 100715 (n¼ 7)
Bradykinin 6678 (n¼ 8) 10577 (n¼ 8) 98712 (n¼ 10)
Carbamylcholine 83711 (n¼ 3) 104718 (n¼ 5) 113725 (n¼ 7)
Cholecystokinin 3179 (n¼ 4) 3274 (n¼ 3) 5675 (n¼ 4)
Neuromedin B 774 (n¼ 4) 2573 (n¼ 3) 150720 (n¼ 4)
Neurotensin — (n¼ 3) — (n¼ 3) 43712 (n¼ 5)
Substance P — (n¼ 3) 3976 (n¼ 3) 72710 (n¼ 3)
Vasopressin — (n¼ 3) 2878 (n¼ 7) 4279 (n¼ 7)
Serum 10578 (n¼ 8) 109715 (n¼ 8) 119719 (n¼ 10)
The GLC19, 16 and 14 SCLC cell lines were loaded with 1 mM Fura2AME washed and resuspended in 2 ml electrolyte
solution and the cell suspension placed in a quartz cuvette and stirred continuously. Neuropeptides were added at 100 nM
concentration and fluorescence was recorded continuously as described in Materials and Methods. Results are expressed as
change in intracellular calcium (nM). The following peptides were also tested at 100 nM –1 mM concentrations and no
increase in [Ca2+]i was ever observed: adrenocorticotrophin hormone, angiotensin 1, atrial natriuretic peptide, calcitonin,
chorionic gonadotropin, dynorphin, b-endorphin, endothelin, epinephrine, galanin, growth hormone-releasing hormone,
gastric-inhibitory peptide, glucagons 5-hydroxytryptamine, Leu-enkephalin, neuropeptide-Y, parathyroid hormone,
substance K, thyrotrophin-releasing hormone.
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Figure 1 Effects of bombesin, neuromedin B, bradykinin, cholecystokinin and serum on [Ca2þ ]i in SCLC cell lines GLC14, GLC16 and GLC19. Cells
loaded with FURA-2-AME were resuspended in electrolyte solution and placed in a quartz cuvette. Fluorescence was monitored and basal and peak [Ca2þ ]i
calculated as described in Materials and Methods. Panel A: All peptides were added at a final concentration of 100 nM. Abbreviations used: BN, bombesin;
NmB, neuromedin B; BK, bradykinin; CCK, cholecystokinin. Serum was added at a final concentration of 1% v v1. Panel B: Dose-dependent effects of
bombesin, neuromedin B, bradykinin and CCK in SCLC cell lines GLC16 and GLC19, open and closed circles, respectively. Peptides were added at the
concentrations indicated. Representative concentration–response relations of three to five experiments are shown. Panel C: mRNA encoding the GRP
receptor was detected by semiquantitative RT–PCR. g-Actin mRNA levels were measured as an internal control for each PCR reaction. The results show a
representative PCR reaction for the GLC14,16 and 19 cell lines. A bar chart showing relative receptor expression, calculated as density of PCR product/actin
is shown for each cell line. The results represent the mean of two independent experiments.
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the number of neuropeptides able to induce a measurable increase
in [Ca2þ ]i and also an increase in the potency of individual
neuropeptides. The expression of the GRP receptor was examined
in the GLC cell lines by RT– PCR (Figure 1C). GRP receptor
expression increased by six-fold in the GLC16 compared to the
GLC14 cell line and by 11-fold in the GLC19 cell line, paralleling
the increased responsiveness to GRP-induced Ca2þ release.
CCK, bradykinin, neuromedin B and bradykinin stimulated a
concentration-dependent increase in clonal growth in the GLC16
and 19 cell lines. There was a significant increase in the ability of
bombesin, neuromedin B and CCK to stimulate clonal growth in
the GLC19 SCLC cell line compared to the GLC16 cell line
(Figure 2). Bradykinin was equally effective in stimulating clonal
growth in both GLC16 and 19 cell lines. The ability of these
neuropeptides to stimulate clonal growth in the GLC14 cell line
was consistently less than that seen in the GLC16 cell line. Serum
stimulated a 405–370% increase in clonal growth in the GLC19, 16
and 14 cell lines, and the cloning efficiency of all three SCLC cell
lines was approximately 1.5%. Hence, the GLC19 cell line develops
increased Ca2þ responsiveness to the neuropeptides CCK,
bombesin and neuromedin B, and this correlates with an increase
in the ability of these neuropeptides to stimulate clonal growth.
SP-G inhibited Ca2þ mobilisation induced by CCK, bombesin,
neuromedin B and bradykinin in the GLC19 SCLC cell line
(Figure 3A). SP-G also inhibited the growth and cloning efficiency
of the GLC14 (not shown) 16 and 19 cells, but was most potent in
the GLC19 cell line (IC50 for the GLC14, 16 and 19 SCLC cells was
25, 25 and 15 mM, respectively, for liquid culture, and 25, 25 and
5 mM, respectively, for cloning efficiency, Figure 3B). Interestingly,
SP-G was still effective in inhibiting the growth of the GLC19 SCLC
line despite the development of resistance to conventional
chemotherapeutic agents (de Vries et al, 1989). These findings
suggest that increased neuropeptide receptor expression results in
increased sensitivity to SP-G.
Sensitivity to SP-G in a panel of tumour cell lines
A panel of tumour cell lines was selected that represents a
spectrum of tumour types, NSCLC, ovarian, pancreatic and colon
cancer, which express neuropeptide receptors in addition to SCLC.
The characteristics of these cell lines and their sensitivity to SP-G
are shown in Table 2. Growth inhibition by SP-G was not confined
to tumour type. The two most sensitive cells were the H69 SCLC
cell line (IC50¼ 10.5 mM) and the HT29 colorectal cell line
(IC50¼ 18 mM). Four out of five SCLC cell lines had IC50 values
below the mean IC50 value of 44 mM. Both the ovarian carcinoma
and the non-small-cell carcinoma were sensitive to growth
inhibition by SP-G, with IC50 values of 31 and 33.5mM, respectively.
During the phase 1 clinical trial of SP-G, plasma levels of up to
40 mM were achievable with no dose-limiting toxicity (Clive et al,
2001). A total of 72% of the cancer cell lines tested had IC50 values
below or near this concentration. This suggests that ‘broad–
spectrum’ neuropeptide antagonists such as SP-G may be effective
antitumour agents in a variety of cancers other than SCLC.
In vivo sensitivity to SP-G in a panel of tumour cell lines
Four members from the original panel of tumour cell lines were
established as xenografts from their respective cell lines: H69
SCLC, HT29 colon carcinoma, PEO4 ovarian cancer and PANC-1
pancreatic cancer. Typical growth inhibition curves (Figure 4) are
shown for each xenograft after i.p. treatment with 50 mg/kg SP-G.
The HT29 xenograft showed a growth inhibition of 70.4%, 7 days
after the commencement of treatment. In addition, this growth
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Figure 2 Dose-dependent effects of bombesin, BK, CCK and neuromedin B on colony formation in GLC16 and GLC19 SCLC cells. GLC16 (hatched
bars) and GLC19 (filled bars) cells, 3–5 days postpassage, were washed and 104 viable cells per ml were plated in SITA medium containing 0.3% agarose on
top of a base of 0.5% agarose in culture medium as described in Materials and Methods. Both layers contained additions at the nanomolar concentrations
indicated. Cultures were incubated at 371C in a humidified atmosphere at 5% CO2 : 95% air for 21 days and then stained with nitro-tetrazolium blue.
Spontaneous colony formation, that is, in the absence of any exogenously added peptide was 140715 (n¼ 75) and 160720 (n¼ 85), in the cell lines
GLC16 and 19, respectively, and normalised to 100%. Each point represents the mean7s.e.m. of two to four experiments each of five replicates.
*Statistically different from neuropeptide concentration matched GLC16 cells (ANOVA, Po0.05).
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inhibition was maintained over 17 days after the final injection
(Figure 4). The PEO4 ovarian xenograft showed a maximum
growth inhibition of 69.3% at day 7, and in common with HT29,
growth inhibition was also maintained over 17 days beyond the
final injection. The H69 xenograft showed a maximum growth
inhibition of 39.9% to SP-G that was sustained for 10 days after
treatment. The PANC-1 pancreatic tumour cell line was one of the
least-sensitive cells lines to SP-G in vitro and proved to be the
least-sensitive xenograft, with statistically significant growth
inhibition recorded at only two time points, day 7 and day 10
(Figure 4). Overall, these data report, for the first time, that SP-G
has marked in vivo xenograft activity in a variety of tumours
including lung, colon, ovarian and pancreatic cancer, and in
cancers such as ovarian cancer (with in vitro derived chemoresis-
tance), NSCLC and colon cancer, which are relatively insensitive to
standard conventional chemotherapy.
Correlation of neuropeptide receptor expression with
sensitivity to SP-G in a panel of tumour cell lines
The expression of GRP, gastrin, BK2 and V1A receptors were
examined by RT–PCR, in nine cell lines from the original panel
representing a spectrum of sensitivity to SP-G. The results are
shown in Table 2 and Figure 5 (n¼ 4–5 independent experiments).
Receptors for vasopressin (V1AR) were detected in four out of four
lung cancer cell lines (three SCLC and one NSCLC). The WX330
SCLC cell line was the highest expresser of V1AR. The pancreatic
and ovarian cancer lines expressed low levels of the V1AR and in
the colorectal cancer cell lines only HT29 cells expressed V1AR.
GRPRs were detected in three out of four lung cancer cell lines
(two SCLC and one NSCLC). In the colorectal cell lines, the HT29
cell line showed high levels of GRPR expression and HCT116 cell
line showed no detectable GRPR expression with intermediate
expression in the HT18 cell line. The pancreatic cell line PANC1
had very low levels of GRPR expression. The PEO4 ovarian cancer
cell line and H69 SCLC cell lines showed high expression of the
GRPR (Table 2). Receptors for bradykinin were detected in all cells
of the cell panel. Other studies have found an almost ubiquitous
expression of bradykinin receptors in human lung cancers (Bunn
et al, 1992). Gastrin receptors were detected in three out of four
lung lines (two SCLC and one NSCLC) and low expression was
detected in the ovarian line PEO4. The highest expression was in
the SCLC cell line H510. Interestingly, none of the colorectal cell
lines expressed gastrin receptors (Table 2). This finding confirms
other studies, which show that the gastrin receptor is rarely
expressed in colorectal cancer cell lines (Reubi et al, 1997). These
results show that sensitivity to SP-G in a variety of tumours
appears to correlate with the level of expression of neuropeptide
receptors. In particular, of all the neuropeptide receptors
examined, the correlation between relative GRP receptor expres-
sion (receptor/g-actin) and sensitivity to SP-G was the most
apparent (Spearmans correlation R¼0.75; P¼ 0.026, Figure 5).
Effect of GRP receptor expression on SP-G sensitivity
in fibroblasts
The importance of neuropeptide receptor status for cell sensitivity
to SP-G was further tested in a rat-1 fibroblast system in which
only one neuropeptide receptor (the mouse GRPR) was expressed
at high levels (Kd¼ 1 nM, Bmax¼ 105 receptors per cell) (Charles-
worth et al, 1996). In native rat-1a fibroblasts, bombesin and other
Ca2þ -mobilising neuropeptides, vasopressin, neurotensin, brady-
kinin and gastrin, failed to mobilise intracellular Ca2þ , suggesting
absence of receptors in the parent cell line (Figure 6A). Rat-1a
fibroblast cells stably expressing the mammalian bombesin
receptor (BOR15) respond normally to bombesin stimulation in
terms of signal transduction and stimulation of DNA synthesis
(Charlesworth et al, 1996; MacKinnon et al, 2001). Bombesin
stimulated a marked and rapid increase in [Ca2þ ]i in BOR15 cells,
which was blocked by Sp-G (Figure 6B). The effect of SP-G on the
growth of rat-1a fibroblasts and BOR15 cells was therefore
determined. The parent rat-1a cells were comparatively resistant
to SP-G-mediated growth inhibition with only partial inhibition
observed at the highest concentration of SP-G (41þ 12% inhibition
at 100mM, IC504100 mM), whereas BOR15 cell growth was
completely inhibited by 80 mM SP-G (IC50 44 mM, Figure 6). These
results show that the presence of the bombesin receptor leads to
increased sensitivity to growth inhibition by SP-G in fibroblasts.
DISCUSSION
The GLC14, 16 and 19 are classic type SCLC cell lines derived from
a 55-year-old female with SCLC. The GLC14 cell line was
established from a supraclavicular lymph node before treatment.
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Figure 3 (A) Effect of SP-G on neuropeptide-induced Ca2þ mobilisa-
tion in GLC19 SCLC cells. Cells loaded with FURA-2-AME were
resuspended in electrolyte solution and placed in a quartz cuvette.
Fluorescence was monitored and basal and peak [Ca2þ ]i calculated as
described in Materials and Methods. Peptides were added at a final
concentration of 30 nM and SP-G at a final concentration of 30mM. (B)
Effect of SP-G on GLC16 and GLC19 cell growth. Liquid growth (upper
panel): GLC16 (triangles) and GLC19 (squares) SCLC cells were
resuspended at a density of 5 104 cells in 1 ml SITA in the presence or
absence of SP-G in triplicate. The controls (cells in absence of antagonist)
after an initial lag period grew exponentially and then reached a plateau
after 10 days (GLC19: 4.870.5 105 (n¼ 6) and GLC16: 5.770.5 105
(n¼ 6)). Each point represents the mean cell number after 10 days7s.e.m.
of two experiments each of three replicates. Colony growth (lower panel):
GLC16 (triangles) and GLC19 (squares) SCLC cultures were washed, and
104 viable cells/ml were plated in SITA medium containing 0.3% agarose on
top of a base of 0.5% agarose in culture medium as described in Materials
and Methods. Both layers contained additions as indicated. Cultures were
incubated at 371C in a humidified atmosphere at 5% CO2 : 95% air for 21
days and then stained with nitro-tetrazolium blue. Each point represents
the mean7s.e.m. of two experiments each of five replicates.
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After chemotherapy, the patient was in complete remission, 4
months later she relapsed. Further chemotherapy resulted in a
partial response and the GLC16 line was established from a
recurrence in the lung. After radiotherapy, the lung appeared
tumour free; however, 3 months later tumour recurred in the lung
from which the GLC19 cell line was derived. This was resistant to
any further treatment and the patient died 2 months later
(Berendsen et al, 1988; de Vries et al, 1989). In vitro sensitivity
to chemotherapeutic agents reflected the clinically observed
development of resistance to treatment (de Vries et al, 1989). We
were also able to confirm these findings in the GLC cells used in
this study (results not shown). One percent serum caused a rapid
and equivalent increase in [Ca2þ ]i in all three GLC SCLC cell lines
suggesting that the mobilisable Ca2þ pools were equivalent in each
of the three cell lines. However, we show that in the progression to
chemoresistance the GLC cells are able to respond to a greater
Table 2 Growth inhibition by SP-G (IC50) and neuropeptide receptor expression in a panel of tumour cell
lines
Relative NP receptor expression
Cell line IC50 (lM) GRPR* V1AR BK2R Gastrin R
H69 (SCLC, Moody et al, 1985) 10.5 0.9170.15 0.870.18 0.6570.31 0.5670.49
HT29 (colorectal, Brattain et al, 1981) 18 0.5570.12 0.0270.01 0.3570.04 —
H510 (SCLC, Moody et al, 1985) 29 0.370.11 1.1070.21 0.5170.17 1.51740.61
PEO4 (ovarian, Lieber et al, 1975) 31 1.3170.25 1.1070.02 0.2470.10 0.270.05
NX002 (NSCLC, Stark et al, 2001) 33.5 1.0170.21 — 0.6570.23 0.5670.28
HRT18 (colorectal, Fogh et al, 1977) 37 0.1870.04 — 0.8070.21 0.0370.01
W X330 (SCLC, Hay et al, 1991) 42 0.0970.01 3.7170.91 0.2270.12 0.2770.18
PANC1 (pancreatic, O’Hara et al, 1986) 58 0.0970.01 0.1070.02 0.3870.11 —
HCT116 (colorectal, Langdon et al, 1988) 129 — — 0.6570.25 —
RT–PCR products were analysed by densitometry and the relative expression level of four neuropeptide receptors are
summarised. These values have been expressed as a ratio of the level of g-actin expression for each cDNA batch and PCR
run. Numbers represent the mean of four to six experiments. Spearman’s rank correlation between IC50 value and receptor
expression level was performed. A significant correlation between sensitivity to SP-G and GRPR expression was confirmed
(Spearman’s R value¼0.75, P¼ 0.026*).
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Figure 4 Effect of SP-G on the growth of H69, HT29, PE04 and PANC-1 xenografts. Four cell lines from the original panel were established as xenografts
from their respective cell lines: H69 SCLC, HT29 colon carcinoma, PEO4 ovarian cancer and PANC-1 pancreatic cancer. Typical growth curves are shown
for each xenograft after i.p. treatment with 50 mg kg1 SP-G (K) or vehicle control (&) as five separate injections administered over 3 days as two
injections on day 1 and 2 separated by a 6-h gap with the final injection given on day 3. The results represent the mean tumour volumes from a single study
(n¼ 6–8). *Statistically significant from vehicle control (Students’ t-test, Po0.05).
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range of neuropeptides with increased potency, and are conse-
quently more sensitive to growth inhibition by SP-G. The GLC19
cell line was more sensitive to SP-G both in liquid culture and in
semisolid medium than the GLC16 and 14 cell lines. The Ca2þ -
mobilisation and the clonal growth results suggest that this cell line
may have greater neuropeptide dependence and this is reflected in
its greater sensitivity to neuropeptide growth factor blocking
agents such as SP-G. This led to the hypothesis that other
neuropeptide-expressing tumours may also be sensitive to the
growth-inhibitory effect of SP-G.
It is well known that neuropeptides can stimulate the growth of
many types of cancers including pancreatic, colorectal, prostate,
ovarian, breast and NSCLC (Bologna et al, 1989; Halmos et al,
1995; Aprikian et al, 1996; Ferris et al, 1997). A panel of 11 tumour
cell lines, which represented a spectrum of tumour types, showed
that sensitivity to SP-G differed across the panel with a range of
41 log order (10mM to 4100 mM). The sensitive cell lines (four
SCLC, two colorectal carcinoma, one NSCLC and 1 ovarian) had
IC50 values that were in the range of physiologically obtainable
plasma concentrations. Moreover, in the cell lines tested in vitro
sensitivity correlated with sensitivity to SP-G in vivo. The results of
this screen suggest that SP-G could be used therapeutically against
several tumour types in addition to SCLC.
We have previously shown that SP-G augments etoposide-
induced growth inhibition and apoptosis in SCLC cells and
suggested that SP-G may be of increased benefit in patients
following relapse or in conjunction with conventional chemother-
apy (MacKinnon et al, 1999). It is of interest to note that the cell
lines SCLC GLC19, ovarian cancer PEO4 and NSCLC NX022, which
in vitro (and in vivo) are resistant to standard chemotherapeutic
agents such as etoposide, are sensitive to the growth-inhibitory
effects of SP-G. This raises the possibility that SP-G may be an
effective anticancer agent in patients with neuropeptide-expressing
tumours which are intrinsically resistant or have acquired
resistance to conventional chemotherapy. A plausible extension
of this hypothesis is that clinically aggressive drug-resistant SCLC
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Figure 5 Upper panel: Correlation between neuropeptide receptor expression and sensitivity to SP-G in tumour cell lines. mRNA encoding the GRP,
V1A, BK2 and gastrin receptors was detected by semiquantitative RT–PCR. g-Actin mRNA levels were measured as an internal control for each PCR
reaction. The results show a representative PCR reaction for each of nine tumour cell lines, which represent a spectrum of sensitivity to SP-G. A bar chart
showing relative receptor expression, calculated as density of PCR product/actin is shown for each receptor. The results represent the mean7s.e.m. of four
independent experiments. Lower panel: Correlation graph between GRPR expression and inhibition of cell growth (IC50) for each of nine tumour cell lines
as indicated (Spearman’s R value¼0.75, P¼ 0.026*).
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cells that emerge after chemotherapy might have a more extensive
network of neuropeptide regulation and therefore display in-
creased sensitivity to neuropeptide antagonists. Further studies in
longitudinal cell lines are required to investigate this hypothesis in
further detail.
Although our data cannot indicate the expression of fully
functional receptors, the RT–PCR approach was taken as it could
be used as a possible diagnostic test in cancer patients to
determine the potential tumour sensitivity to neuropeptide growth
factor antagonist therapy. Of the four neuropeptide receptors
tested, the most apparent correlation was between high expression
of the GRP receptor and increased sensitivity to SP-G. This is in
some ways surprising given that SP-G is more selective for the
V1AR (Seckl et al, 1995) which is expressed on many lung cancer
cells. However, GRP secretion and GRPR expression are the
hallmarks of the neuroendocrine phenotype. The presence of the
GRPR in particular may be a reflection of the general neuroendo-
crine phenotype of the cancer cells indicating greater neuropeptide
dependence for growth. It would be interesting to look at the
expression of other bombesin-like peptide receptors such as the
neuromedin B receptor to assess its role in substance P-analogue-
induced growth inhibition.
The GRPR has been shown to be oncogenic when transfected
into the nonmalignant NCM460 colon epithelial cell line (Ferris
et al, 1997). The increased proliferation was shown to be because
of constitutive activation of the GRPR in that the receptors
tonically coupled to Gq in the absence of ligand. This gives a
potential mechanism whereby the GRPR may act as an oncogene.
In addition, many tumour types such as breast cancer (Halmos
et al, 1995) and prostate cancer (Bologna et al, 1989; Aprikian et al,
1996) have also been shown to aberrently express GRPRs. We and
others have previously shown that the expression of GRPRs in
fibroblasts increases the ability of SP-G and other substance P
analogues to activate the extracellular-signal-regulated kinase
(ERK) and c-jun-N-terminal kinase (JNK) pathways leading to
growth arrest and apoptosis (Jarpe et al, 1998; MacKinnon et al,
2001). Together, these data demonstrate that not only can GRPR
expression transform cells, but these cells then become more
sensitive to substance P-analogue-induced cell death.
These findings have important implications for the design of
more advanced phase human clinical trials using substance P
analogues. SP-G is currently entering a phase II clinical trial where
its effectiveness will be tested in SCLC patients, but ultimately,
compounds of this type may also be suitable for the treatment of a
wide range of other tumour types and neuropeptide-expressing
tumours that have become resistant to standard conventional
chemotherapeutic agents. Screening tumour biopsy samples for
neuropeptide receptor expression may provide insight into the
likelihood of patients responding to treatment with substance P
analogues, analogous to oestrogen receptor expression conferring
efficacy to tamoxifen in breast cancer. It is suggested that tumours
should be biopsied to select patients for substance P-analogue trials
based on the expression of the GRPR and another neuropeptide
receptor. Our results suggest that these tumours should show
growth inhibition regardless of intrinsic or acquired resistance to
standard chemotherapeutic agents. It is therefore proposed that in
the first instance, patients with tumours that express the GRPR and
another neuropeptide receptor who have failed conventional
treatment should be randomised into two groups – best supportive
care and treatment with substance P analogues.
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Figure 6 Expression of the bombesin/GRP receptor in Rat-1 fibroblasts increases sensitivity to growth inhibition by SP-G. Rat-1a fibroblasts (A) or rat-1a
fibroblasts expressing the bombesin receptor (B) were loaded with FURA-2-AME and resuspended in electrolyte solution. Fluorescence was monitored and
basal and peak [Ca2þ ]i calculated as described in Materials and Methods. (A) Rat-1a cells were stimulated with 10 nM each of bombesin (Bn), vasopressin
(Vp), neurotensin (NT) and bradykinin (Bk), 10mM SP-G or 1% FCS. The results are representative of three experiments. (B) (left) Response to 10 nM
bombesin in BOR-15 cells and (right) effect of 10 mM SP-G on bombesin-stimulated Ca2þ release in BOR-15 cells. (C) Rat-1 fibroblasts (closed squares) or
Rat-1 fibroblasts expressing the bombesin receptor (BOR15, open squares) were grown in SITA media in the presence or absence of the indicated
concentrations of SP-G. The cell number was determined and IC50 values calculated following 7 days of growth.
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